- Home
- INKT vs MDCX Comparison
INKT vs MDCX Comparison
Compare INKT & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- MDCX
- Stock Information
- Founded
- INKT 2017
- MDCX 2008
- Country
- INKT United States
- MDCX United States
- Employees
- INKT N/A
- MDCX N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- MDCX
- Sector
- INKT Health Care
- MDCX
- Exchange
- INKT Nasdaq
- MDCX Nasdaq
- Market Cap
- INKT 69.2M
- MDCX 36.2M
- IPO Year
- INKT 2021
- MDCX N/A
- Fundamental
- Price
- INKT $15.35
- MDCX $2.43
- Analyst Decision
- INKT Buy
- MDCX Strong Buy
- Analyst Count
- INKT 3
- MDCX 2
- Target Price
- INKT $37.50
- MDCX $23.50
- AVG Volume (30 Days)
- INKT 41.0K
- MDCX 349.5K
- Earning Date
- INKT 11-13-2025
- MDCX 08-11-2025
- Dividend Yield
- INKT N/A
- MDCX N/A
- EPS Growth
- INKT N/A
- MDCX N/A
- EPS
- INKT N/A
- MDCX N/A
- Revenue
- INKT N/A
- MDCX N/A
- Revenue This Year
- INKT N/A
- MDCX N/A
- Revenue Next Year
- INKT N/A
- MDCX N/A
- P/E Ratio
- INKT N/A
- MDCX N/A
- Revenue Growth
- INKT N/A
- MDCX N/A
- 52 Week Low
- INKT $4.56
- MDCX $1.79
- 52 Week High
- INKT $76.00
- MDCX $8.94
- Technical
- Relative Strength Index (RSI)
- INKT 52.36
- MDCX 55.40
- Support Level
- INKT $13.11
- MDCX $2.34
- Resistance Level
- INKT $16.20
- MDCX $2.11
- Average True Range (ATR)
- INKT 1.10
- MDCX 0.21
- MACD
- INKT 0.05
- MDCX 0.08
- Stochastic Oscillator
- INKT 72.47
- MDCX 71.11
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About MDCX Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.